SecBot SecBot
Biotech Drug Report Generated Jul 3, 2026

IOV-4001

IOVA·IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/2
Time to market
5+ years (Phase 1/2; furthest Phase 2 efficacy portion ongoing; regulatory filing unlikely before 2028-2029 if successful)
Why 4/10
The next hard catalyst is Phase 2 efficacy data from the IOV-GM1-201 trial in previously treated advanced melanoma, originally guided for Q1 2026 but not yet prominently reported as of July 2026. The data may have been delayed or presented quietly. Because IOV-4001 is one of several pipeline programs at a company whose primary value driver is already-approved/commercialized Amtagvi, the impact score is capped at 4, a positive readout would boost the pipeline narrative but is not make-or-break for IOVA.
Actionable Insight NEUTRAL

Watch for IOV-4001 Phase 2 efficacy data from the melanoma cohort of IOV-GM1-201, which was expected in early 2026 and may be reported later this year. Positive data would validate Iovance's next-generation TIL platform and could lift the stock, but IOVA's near-term value is primarily tied to Amtagvi commercial execution. The 2026 revenue guidance of $350M-$370M and Q2 earnings (around Aug 6, 2026) are more immediate catalysts.

Price Chart

Loading chart...

Executive Summary

IOV-4001 is Iovance Biotherapeutics' first genetically modified tumor-infiltrating lymphocyte (TIL) therapy, using TALEN gene-editing (licensed from Cellectis) to knock out the PD-1 checkpoint gene. It is designed for patients with advanced melanoma and non-small cell lung cancer who have progressed on prior anti-PD-1 therapy. Currently in a Phase 1/2 trial, IOV-4001 is an early-stage pipeline asset at a company whose primary revenue driver is the already-approved TIL therapy Amtagvi (lifileucel), which generated ~$264M in full-year 2025 product revenue. IOVA has 13 Buy/Strong Buy ratings, 3 Hold, 0 Sell with a mean analyst price target of $8.80 (~177% upside from ~$4.31). The Phase 2 efficacy data, originally guided for Q1 2026, has not been prominently reported, suggesting possible delays.

How It Works

IOV-4001 is a personalized cell therapy made from a patient's own immune cells (T cells) that are extracted from their tumor, genetically modified in a lab using TALEN gene-editing technology to disable the PD-1 "off switch," multiplied into billions, and then infused back into the patient. This creates T cells that can recognize and attack the cancer without being suppressed by the tumor's PD-1/PD-L1 checkpoint pathway, essentially combining the benefits of cell therapy and immune checkpoint blockade in a single treatment.

Trial Status

First-in-human Phase 1/2 open-label study (IOV-GM1-201; NCT05361174) evaluating IOV-4001 in ~53 patients with unresectable/metastatic melanoma or Stage III/IV NSCLC. Phase 1 safety run-in assessed dose-limiting toxicities; Phase 2 efficacy portion (enrolling previously treated advanced melanoma and NSCLC) was described as "enrolling rapidly" in early 2025 with data originally anticipated for Q1 2026. As of July 2026, the latest corporate updates indicate the trial is ongoing without definitive topline data having been released.

The Two-Sided Case

▲ Bull Case4
IOV-4001 is the first gene-edited TIL therapy to enter the clinic, combining TIL efficacy with intrinsic PD-1 blockade in a single infusion, potentially eliminating the need for separate checkpoint inhibitor drugs and their systemic side effects.
Iovance is the leader in commercialized TIL therapy (Amtagvi was the first FDA-approved TIL for solid tumors), giving it real-world manufacturing and commercial infrastructure that competitors lack.
Analyst consensus is heavily bullish: 13 Buy/Strong Buy vs 3 Hold vs 0 Sell, with a mean price target of $8.80 (177% implied upside) as of July 2026.
Iovance guided $350M-$370M in 2026 revenue (36% YoY growth), providing cash to fund pipeline programs like IOV-4001 without near-term dilution risk.
▼ Bear Case5
IOV-4001 is still in Phase 1/2 with no publicly reported efficacy data as of July 2026, despite the Phase 2 data having been anticipated in Q1 2026, suggesting possible delays or underwhelming interim results.
The TIL therapy approach requires complex, individualized manufacturing (tumor resection, cell expansion, infusion), which is slow, expensive, and limits scalability vs. off-the-shelf immunotherapies.
Iovance faces competition from other TIL developers (Instil Bio, Turnstone Biologics) and established checkpoint inhibitors from Merck (Keytruda) and BMS (Opdivo/Yervoy) that already dominate the melanoma and NSCLC markets.
The company is not yet profitable, Q1 2026 EPS of -$0.36 missed estimates, and operating losses continue despite growing Amtagvi revenue. IOVA cut 19% of its workforce in 2025 to extend cash runway.
Short interest has shown elevated signals (57% short ratio on July 1, 2026), indicating significant bearish positioning.

Upcoming Catalysts

  • Phase 2 efficacy data from IOV-GM1-201 trial in previously treated advanced melanoma (expected but delayed from Q1 2026)
  • Q2 2026 earnings report (~Aug 6, 2026), Amtagvi revenue trajectory, pipeline updates, and any IOV-4001 data timing guidance
  • Potential presentation of IOV-4001 data at a major medical conference in H2 2026
  • NSCLC milestone: completion of enrollment in IOV-LUN-202 (lifileucel) with updated dataset

Source Filing

The SecBot filing or press-release report that triggered this drug report:

IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report

Sources · 16

Hover a chip for the title
1 iovance.com2 tipranks.com3 nasdaq.com4 zacks.com5 ts2.tech6 iovance.com7 iovance.com8 cgtlive.com9 minichart.com.sg10 sec.gov11 jitc.bmj.com12 pharmaceutical-technology.com13 synapse.patsnap.com14 finviz.com15 delveinsight.com16 globenewswire.com